OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/NTRK1
Lung Cancer — Non-Small Cell (NSCLC)NTRK1 Clinical Trials
NTRK1 fusions are rare drivers in NSCLC (<1%) but respond to tumor-agnostic NTRK inhibitors larotrectinib and entrectinib, both FDA-approved regardless of cancer type. Resistance emerges via acquired kinase domain mutations. Trials investigate next-generation NTRK inhibitors designed to overcome on-target resistance.
Top recruiting NTRK1 Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and US site count. See all 19 trials matched to your profile →
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NovoCure GmbH
Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC
Shouyao Holdings (Beijing) Co. LTD
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Sinocelltech Ltd.
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
Guangdong Provincial People's Hospital
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network